A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Phase 2
200
about 2.7 years
18+
8 sites in GA, MI, NJ +3
What this study is about
This trial is testing a treatment called raludotatug deruxtecan (R-DXd) for people with advanced or metastatic solid tumors. The goal is to see if R-DXd can help improve the lives of those who have these types of cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Raludotatug deruxtecan
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only), Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts), Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
Secondary: Disease Control Rate (DCR) as Assessed by the Investigator (All Cohorts Except ccRCC Cohort), Duration of Response (DoR) as Assessed by the Investigator, Objective Response Rate as Assessed by the Investigator (ccRCC Cohort Only), Pharmacokinetic Parameter Maximum Concentration (Cmax) of R-DXd, Progression-free Survival (PFS) as Assessed by the Investigator
Oncology